Figure 2.

Clinical and molecular response to treatment in feline oral SCC treated with TBG-RNAi-fCK2αα′. (A) Clinical response in one cat (cat 8; see Table 2). Panels i and ii: Pretreatment, tumor affecting right maxilla and facial soft tissues. Panels iii and iv: Posttreatment. There has been a 40% reduction in longest tumor diameter, which has resulted in an open wound externally on the right lateral muzzle (arrow, iii) and progression of the defect in the maxilla (arrow, iv). (B) CK2α IHC in oral SCC pretreatment (panel i) and posttreatment (panel ii) in one cat (cat 4; see Table 2). There is reduced CK2α labeling in the posttreatment (score 1) sample compared with the pretreatment (score 2) sample. In the pretreatment sample, CK2α labeling is present in both the nucleus and cytoplasm of tumor cells (*). In the posttreatment sample, CK2α labeling is present only in scattered nuclei (arrow shows example) and is of lower intensity overall. Color images available online at www.liebertpub.com/humc